Woodcliff, NJ - Endo International plc and Woodcliff Lakes-based Par Pharmaceutical Holdings, Inc. today announced that they have entered into a definitive agreement under which Endo will acquire privately-held Par from TPG in a transaction valued at $8.05 billion, including assumption of Par debt. The combination will create a leading specialty pharmaceutical company with a generics business that is one of the industry’s fastest growing and among the top five as measured by U.S. sales. It is also expected to help drive long-term double-digit revenue growth for Endo.
0 Comments
Jersey City, NJ - According to John Lechleiter of Forbes, "If you are a regular reader of politically oriented commentaries on the pharmaceutical industry then you are familiar with, and perhaps even subscribe to, what I call “the Big Five”—myths about this industry that routinely poison debates, obscure genuine problems, and distort policy recommendations on health care. These myths have been all over the public arena again recently, and it’s time to confront them systematically."
Bridgewater, NJ - Celgene's expansive approach to partnering continues to bear fruit, as two of the Big Biotech's in-licensed treatments have been added to the FDA's fast-track program, promising a speedy regulatory review as each approaches Phase III.
Montclair, NJ -- Elephantiasis, or lymphatic filariasis, is a parasitic disease infecting more than 120 million people in the tropics. According to the World Health Organization, nearly 40 million of them are disfigured and disabled by the infectious disease. Characterized by elephantine enlarged limbs and thickened skin, lymphatic filariasis is caused by a parasite transmitted to humans by mosquito bites.
Trenton, NJ – Proposed legislation that will allow greater patient access to more affordable FDA-approved biologic medicines was passed unanimously by the New Jersey Assembly Health and Human Services Committee today. The bill, A2477, also includes provisions for physician notification when a biosimilar bill is substituted for a biologic drug.
Teaneck, NJ – According to Hugh Morley of the Record, “Former medical company executive, Dr. Joseph V. Gulfo doesn't want to fight anymore. And that's good news for Fairleigh Dickinson University.” After two years battling to get a melanoma detection device approved by the U.S. Food and Drug Administration, the former CEO of Mela Sciences is now the FDU's Rothman Institute of Innovation and Entrepreneurship.
Trenton, NJ – In a press conference this week, the New Jersey Senate Republican leadership released a 36 bill package to improve the state of innovation, the strengthen the workforce and grow the economy. The bills seek to usher in growth through policies pertaining to science and technology, STEM education, improving the state’s existing economic development practices, regulation reductions as well as agriculture enhancements without adding additional costs to the budget.
Washington D.C. – According to Thomas Peter Stossel of the American Enterprise Institute, “Over the years I have practiced medicine, U.S. longevity has increased by a decade, deaths from the commonest killer, cardiovascular disease, have dropped by 60 percent, and cancer deaths, the second most prevalent cause, are at an all-time low. HIV-infected individuals, once doomed, live normal albeit medicated lives. Arthritis sufferers previously condemned to pain, crutches and wheelchairs enjoy relative comfort and mobility. Unfortunately, three pernicious myths conspire to undermine such optimism.”
Trenton, NJ – According to Linda Johnson of The Associated Press, “The global pharmaceutical industry is pouring billions of dollars into developing treatments for rare diseases, which once drew little interest from major drug makers but now point the way toward a new era of innovative therapies and big profits. The investments come as researchers harness recent scientific advances, including the mapping of the human genome, sophisticated and affordable genetic tests, and laboratory robots that can screen thousands of compounds per hour in search of the most potent ones.”
|
Do not miss a single innovative moment and sign up for our newsletter!
|